The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study on third-line chemotherapy combined bevacizumab with S-1 for metastatic colorectal cancer with mutated KRAS: SAVIOR study.
Akinori Takagane
Honoraria - Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
Yasuhiro Miyake
Honoraria - Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
Kouji Kobayashi
Honoraria - Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
Naoki Nagata
Honoraria - Chugai Pharma; Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
Atsushi Sato
Honoraria - Chugai Pharma; Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
Yutaka Ogata
Honoraria - Chugai Pharma; Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
Mutsumi Fukunaga
Honoraria - Chugai Pharma; Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
Koki Otsuka
Honoraria - Chugai Pharma; Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
Takao Takahashi
Honoraria - Chugai Pharma; Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
Hidetomo Matsumoto
Research Funding - Taiho Pharmaceutical
Yuji Negoro
Honoraria - Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
Yoshihiro Matsubara
No relevant relationships to disclose
Motoki Yoshida
Honoraria - Chugai Pharma; Taiho Pharmaceutical
Research Funding - Chugai Pharma; Taiho Pharmaceutical; Taiho Pharmaceutical